ReviewDisease models & mechanisms2017
Human tissue models in cancer research: looking beyond the mouse.
Review in Disease models & mechanisms, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 60 citations in OpenAlex.
- Accessing the DNA in Breast Tissue: Adhesive Cell Capture from Flow onto Fibers of Cellulose Papers.ACS applied materials & interfaces · 2026Article
- Review
- Establishment of Breast Cancer Organoids: A Systematic Review and Meta-Analysis.International journal of breast cancer · 2026Article
- Preclinical Applications of Magnetic Resonance Imaging in Oncology.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- Melatonin suppresses cancer cell proliferation, DNA repair and expression of the oncogene TRIP13.Cell death discovery · 2025Article
- Potential of ex vivo organotypic slice cultures in neuro-oncology.Neuro-oncology · 2025Review
- Human 3D Lung Cancer Tissue Photothermal Therapy Using Zn- and Co-Doped Magnetite Nanoparticles.ACS biomaterials science & engineering · 2025Article
- A promising breakthrough in pancreatic cancer research: The potential of spheroids as 3D models.BioImpacts : BI · 2025Review
- (3D) Bioprinting-Next Dimension of the Pharmaceutical Sector.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Modelling acute myeloid leukemia (AML): What's new? A transition from the classical to the modern.Drug delivery and translational research · 2023Review
- An Update on Adipose-Derived Stem Cells for Regenerative Medicine: Where Challenge Meets Opportunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Animal Models and Their Role in Imaging-Assisted Co-Clinical Trials.Tomography (Ann Arbor, Mich.) · 2023Review
- (Bio)printing in Personalized Medicine-Opportunities and Potential Benefits.Bioengineering (Basel, Switzerland) · 2023Review
- In Vitro Cancer Models: A Closer Look at Limitations on Translation.Bioengineering (Basel, Switzerland) · 2022Review
- Establishment of a ccRCC patient-derived chick chorioallantoic membrane model for drug testing.Frontiers in medicine · 2022Article
- Co-Clinical Trials: An Innovative Drug Development Platform for Cholangiocarcinoma.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Using Spheroids as Building Blocks Towards 3D Bioprinting of Tumor Microenvironment.International journal of bioprinting · 2021Review
- Cancer Explant Models.Current topics in microbiology and immunology · 2021Article
- Emulating Human Tissues and Organs: A Bioprinting Perspective Toward Personalized Medicine.Chemical reviews · 2020Review
- Integrating Systems Biology and an Ex Vivo Human Tumor Model Elucidates PD-1 Blockade Response Dynamics.iScience · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mouse models, including patient-derived xenograft mice, are widely used to address questions in cancer research. However, there are documented flaws in these models that can result in the misrepresentation of human tumour biology and limit the suitability of the model for translational research. A coordinated effort to promote the more widespread development and use of 'non-animal human tissue' models could provide a clinically relevant platform for many cancer studies, maximising the opportunities presented by human tissue resources such as biobanks. A number of key factors limit the wide adoption of non-animal human tissue models in cancer research, including deficiencies in the infrastructure and the technical tools required to collect, transport, store and maintain human tissue for lab use. Another obstacle is the long-standing cultural reliance on animal models, which can make researchers resistant to change, often because of concerns about historical data compatibility and losing ground in a competitive environment while new approaches are embedded in lab practice. There are a wide range of initiatives that aim to address these issues by facilitating data sharing and promoting collaborations between organisations and researchers who work with human tissue. The importance of coordinating biobanks and introducing quality standards is gaining momentum. There is an exciting opportunity to transform cancer drug discovery by optimising the use of human tissue and reducing the reliance on potentially less predictive animal models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.